ValuEngine lowered shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a strong-buy rating to a buy rating in a research note issued to investors on Friday morning.

Several other analysts have also recently commented on GLPG. Stifel Nicolaus dropped their target price on shares of GALAPAGOS NV/S from $120.00 to $109.00 and set a buy rating for the company in a research report on Friday, June 29th. Zacks Investment Research raised shares of GALAPAGOS NV/S from a hold rating to a buy rating and set a $109.00 price target for the company in a report on Wednesday, June 27th. Royal Bank of Canada decreased their price target on shares of GALAPAGOS NV/S to $94.00 and set a sector perform rating for the company in a report on Friday, June 29th. Credit Suisse Group set a $92.00 price target on shares of GALAPAGOS NV/S and gave the company a hold rating in a report on Tuesday, August 7th. Finally, BidaskClub lowered shares of GALAPAGOS NV/S from a buy rating to a hold rating in a report on Thursday, June 14th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $109.00.

Shares of GALAPAGOS NV/S stock traded down $0.40 on Friday, hitting $101.34. 51,070 shares of the company’s stock traded hands, compared to its average volume of 101,203. The stock has a market capitalization of $5.55 billion, a price-to-earnings ratio of -38.39 and a beta of 2.12. GALAPAGOS NV/S has a one year low of $84.13 and a one year high of $121.09.

Hedge funds have recently made changes to their positions in the company. AMP Capital Investors Ltd acquired a new position in shares of GALAPAGOS NV/S in the 2nd quarter valued at $221,000. Provident Investment Management Inc. acquired a new position in shares of GALAPAGOS NV/S in the 2nd quarter valued at $249,000. Citadel Advisors LLC boosted its stake in GALAPAGOS NV/S by 24.3% in the 1st quarter. Citadel Advisors LLC now owns 3,566 shares of the biotechnology company’s stock worth $356,000 after purchasing an additional 696 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in GALAPAGOS NV/S in the 1st quarter worth $636,000. Finally, Stanley Laman Group Ltd. acquired a new position in GALAPAGOS NV/S in the 2nd quarter worth $720,000. 17.38% of the stock is owned by institutional investors.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Recommended Story: How to Use the New Google Finance Tool

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.